China Pharma Holdings (CPHI) Receivables - Net (2010 - 2026)

China Pharma Holdings' Receivables - Net history runs 17 years deep, the most recent figure standing at $196262.0 for Q1 2026.

• Quarterly Receivables - Net fell 40.33% year-over-year to $196262.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $196262.0 (down 40.33% YoY) and the FY2025 annual result came in at $254435.0, down 98.16% from the prior year.
• Receivables - Net was $196262.0 for Q1 2026 at China Pharma Holdings, down from $254435.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $14.3 million in Q4 2023 and bottomed at $39019.0 in Q1 2022.
• A 5-year average of $4.3 million and a median of $254850.0 in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 13063.85% — and 2025, when it sank 98.43%.
• China Pharma Holdings' Receivables - Net stood at $421531.0 in 2022, then jumped by 3290.15% to $14.3 million in 2023, then decreased by 3.3% to $13.8 million in 2024, then slumped by 98.16% to $254435.0 in 2025, then slipped by 22.86% to $196262.0 in 2026.
• Business Quant data shows CPHI's Receivables - Net at $196262.0 in Q1 2026, $254435.0 in Q4 2025, and $224638.0 in Q3 2025.